Simon de Denus1,2,3, Grégoire Leclair1, Marie-Pierre Dubé2,3,4, Isabelle St-Jean1, Yassamin Feroz Zada2,3, Essaïd Oussaïd2,3, Martin Jutras1, Michael M Givertz5, Robert J Mentz6, W H Wilson Tang7, João Pedro Ferreira8, Jean Rouleau2,4, Javed Butler9, Andreas P Kalogeropoulos10. 1. Faculty of Pharmacy, Montreal, Canada. 2. Montreal Heart Institute, Montreal, Canada. 3. Université de Montreal Beaulieu-Saucier Pharmacogenomics Center, Montreal, Canada. 4. Medicine, Université de Montréal, Montreal, Canada. 5. Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. 6. Department of Medicine, Duke University, Durham, NC, USA. 7. Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH, USA. 8. Université de Lorraine, Inserm, Centre d'Investigations Cliniques-Plurithématique 14-33, and Inserm U1116, CHRU, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France. 9. Department of Medicine, Stony Brook University, Stony Brook, NY, USA. 10. Department of Medicine, Emory University, Atlanta, Georgia.
Abstract
AIMS: In Aldosterone Targeted Neurohormonal Combined with Natriuresis Therapy in Heart Failure (ATHENA-HF), high-dose spironolactone (100 mg daily) did not improve efficacy endpoints over usual care [placebo or continued low-dose spironolactone (25 mg daily) in patients already receiving spironolactone] in the treatment of acute heart failure (HF). We hypothesized that low concentrations of the long-acting active metabolites of spironolactone [canrenone and 7α-thiomethylspironolactone (7α-TMS)] in the high-dose group could have contributed to these neutral results. METHODS AND RESULTS: In patients randomized to high-dose spironolactone not previously treated with spironolactone (high-dose-naïve, n = 112), concentrations of canrenone and 7α-TMS increased at 48 and 96 h compared to baseline, and between 48 and 96 h (all P < 0.005), indicating that steady-state concentrations had not been reached by 48 h. In patients previously on low-dose, high-dose spironolactone (high-dose-previous, n = 37), concentrations of canrenone increased at 48 and 96 h compared to baseline (both P < 0.0005), with a marginal increase between 48 and 96 h (P = 0.0507). At 48 h, both high-dose groups had higher concentrations of both metabolites than the low-dose spironolactone group (P < 0.0001). Moreover, concentrations of both metabolites were higher in high-dose-previous vs. high-dose-naïve patients (P < 0.01), indicating that previous spironolactone use was significant, and that steady-state has not been reached in high-dose-naïve patients at 48 h. We found limited and inconsistent evidence of correlation between metabolite concentrations and endpoints. CONCLUSIONS: Lower-than-anticipated concentrations of spironolactone active metabolites were observed for at least 48 h in the high-dose spironolactone group and may have contributed to the absence of pharmacological effects of spironolactone in the ATHENA-HF trial.
RCT Entities:
AIMS: In Aldosterone Targeted Neurohormonal Combined with Natriuresis Therapy in Heart Failure (ATHENA-HF), high-dose spironolactone (100 mg daily) did not improve efficacy endpoints over usual care [placebo or continued low-dose spironolactone (25 mg daily) in patients already receiving spironolactone] in the treatment of acute heart failure (HF). We hypothesized that low concentrations of the long-acting active metabolites of spironolactone [canrenone and 7α-thiomethylspironolactone (7α-TMS)] in the high-dose group could have contributed to these neutral results. METHODS AND RESULTS: In patients randomized to high-dose spironolactone not previously treated with spironolactone (high-dose-naïve, n = 112), concentrations of canrenone and 7α-TMS increased at 48 and 96 h compared to baseline, and between 48 and 96 h (all P < 0.005), indicating that steady-state concentrations had not been reached by 48 h. In patients previously on low-dose, high-dose spironolactone (high-dose-previous, n = 37), concentrations of canrenone increased at 48 and 96 h compared to baseline (both P < 0.0005), with a marginal increase between 48 and 96 h (P = 0.0507). At 48 h, both high-dose groups had higher concentrations of both metabolites than the low-dose spironolactone group (P < 0.0001). Moreover, concentrations of both metabolites were higher in high-dose-previous vs. high-dose-naïve patients (P < 0.01), indicating that previous spironolactone use was significant, and that steady-state has not been reached in high-dose-naïve patients at 48 h. We found limited and inconsistent evidence of correlation between metabolite concentrations and endpoints. CONCLUSIONS: Lower-than-anticipated concentrations of spironolactone active metabolites were observed for at least 48 h in the high-dose spironolactone group and may have contributed to the absence of pharmacological effects of spironolactone in the ATHENA-HF trial.
Authors: Simon de Denus; Eileen O'Meara; Akshay S Desai; Brian Claggett; Eldrin F Lewis; Grégoire Leclair; Martin Jutras; Joël Lavoie; Scott D Solomon; Bertram Pitt; Marc A Pfeffer; Jean L Rouleau Journal: N Engl J Med Date: 2017-04-27 Impact factor: 91.245
Authors: Kirkwood F Adams; Gregg C Fonarow; Charles L Emerman; Thierry H LeJemtel; Maria Rosa Costanzo; William T Abraham; Robert L Berkowitz; Marie Galvao; Darlene P Horton Journal: Am Heart J Date: 2005-02 Impact factor: 4.749
Authors: João Pedro Ferreira; Mário Santos; Sofia Almeida; Irene Marques; Paulo Bettencourt; Henrique Carvalho Journal: Eur J Intern Med Date: 2013-09-23 Impact factor: 4.487
Authors: P Gardiner; K Schrode; D Quinlan; B K Martin; D R Boreham; M S Rogers; K Stubbs; M Smith; A Karim Journal: J Clin Pharmacol Date: 1989-04 Impact factor: 3.126
Authors: Susan Stienen; Khibar Salah; Cathelijne Dickhoff; Valentina Carubelli; Marco Metra; Laura Magrini; Salvatore Di Somma; Jan P Tijssen; Yigal M Pinto; Wouter E Kok Journal: J Card Fail Date: 2015-07-26 Impact factor: 5.712
Authors: Nicolas Girerd; Peter S Pang; Karl Swedberg; Angela Fought; Mary J Kwasny; Haris Subacius; Marvin A Konstam; Aldo Maggioni; Mihai Gheorghiade; Faiez Zannad Journal: Eur J Heart Fail Date: 2013-06-19 Impact factor: 15.534
Authors: Jonathan G Amatruda; Rebecca Scherzer; Veena S Rao; Juan B Ivey-Miranda; Michael G Shlipak; Michelle M Estrella; Jeffrey M Testani Journal: Kidney Med Date: 2022-04-08